Navigation Links
New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder

were similar for all treatment groups -- 91 percent reported at least one adverse event in the placebo/desvenlafaxine succinate group; 86 percent in the venlafaxine ER/desvenlafaxine succinate group; and 86 percent in the desvenlafaxine succinate/desvenlafaxine succinate group. The incidence of nausea was highest for the placebo/desvenlafaxine succinate group during the first week of treatment and decreased to rates similar to the venlafaxine ER/desvenlafaxine succinate group (p= 0.03) and the desvenlafaxine succinate/desvenlafaxine succinate group at Day 8 and beyond. Additionally, discontinuation rates due to adverse events were highest in the placebo/desvenlafaxine succinate group and lowest in the desvenlafaxine succinate/desvenlafaxine succinate group (placebo/desvenlafaxine succinate: 23 percent; venlafaxine ER/desvenlafaxine succinate: 16 percent; desvenlafaxine succinate/desvenlafaxine succinate: 11 percent).

Poster NR299: Feiger AD, et al. A Placebo-Controlled Efficacy and Safety Study of a Flexible Dose of Desvenlafaxine Succinate in Outpatients with Major Depressive Disorder

According to the results of a Phase 3, multicenter, double-blind, placebo- controlled, parallel-group, flexible-dose study, there was no significant difference between patients receiving placebo and those receiving desvenlafaxine succinate based on the primary endpoint of change from baseline in the HAM-D17 total score at the final evaluation of Week 8, using analysis of co-variance with last-observation-carried-forward (LOCF) analyses. However, based on observed-cases analysis of the primary endpoint, there was a significant difference at Week 8 between patients who took desvenlafaxine succinate vs. patients receiving placebo. Based on LOCF and observed-case analysis of various secondary endpoints, desvenlafaxine succinate was significantly better than placebo.

Patients in this study were randomized to receive desvenlafaxine succinate 200 to 400 mg/day (n=117) o
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/19/2014)... Mich. , Sept. 19, 2014  Diplomat, the ... of David Dreyer to the Board of ... independent director and will also serve as chair of ... almost 30 years of accounting, financial, compliance and operating ... Mr. Dreyer has served as chief financial officer, chief ...
(Date:9/19/2014)... 2014 According to market ... Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, ... Rotary) & Geography - Global Trends & Forecast ... the lyophilization market on the basis of various ... of the market size of each of these ...
(Date:9/19/2014)... , Sept. 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX ® in the ... that BioSpecifics, President, Tom Wegman , will present a ... in the Biotech Industry Conference. The presentation ... p.m. EDT at the Millennium Broadway Hotel in ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2
... Fla., May 8, 2012 Grappling with economic uncertainty, ... industry is on the cusp of major changes, said ... opening session of the 2012 GHX Healthcare Supply Chain ... GPOs and distributors gathered this week in Orlando for ...
... DIEGO, May 8, 2012 Aethlon Medical, Inc. ... filtration devices to address infectious disease, cancer and other ... C virus (HCV) is currently undetectable in all infected ... in combination with peginterferon+ribavirin (PR) drug therapy and monitored ...
Cached Medicine Technology:GHX Reveals Roadmap to Stronger Healthcare Community at GHX Healthcare Supply Chain Summit 2GHX Reveals Roadmap to Stronger Healthcare Community at GHX Healthcare Supply Chain Summit 3Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy 2Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy 3Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy 4Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy 5
(Date:9/20/2014)... 20, 2014 Lifeinsurancequoteterm.net has released ... no medical exam life insurance plan provides for vulnerable ... family members should be a top priority for every ... insurance without taking medical examinations and visiting a doctor. ... medical examinations will provide coverage up to $300,000, but ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Ticket Down ... concert tickets for her 2015 “Honeymoon Tour.” This ... ARIANA-2015 for added savings. , In early 2015, fans will ... in the world across North America. Twenty-one-year-old Ariana Grande will ... which will take her to 25 cities across the United ...
(Date:9/20/2014)... 20, 2014 Recently, Best Cheap ... has launched its new website. The new site ... popular hosting products for customers. Here, people can ... a purchasing decision. Also, it has recommended some ... , One of the great web hosting suppliers, ...
(Date:9/20/2014)... September 20, 2014 Recently, UWDress.com, an ... and women’s special occasion outfits, has launched a special ... company’s prom outfits are popular among worldwide clients. Now, ... wholesale prom dresses on its website. , ... customers from around the world. Great custom made items ...
(Date:9/20/2014)... RBSEO Services, which has occupied a ... announced it provides an affordable website SEO (Search Engine ... announcement would benefit those new and old businesses struggling ... afford to pay a big amount for their website ... websites in top search results for their business keywords ...
Breaking Medicine News(10 mins):Health News:No Medical Exam Life Insurance Provides Financial Protection for Families 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 3Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Discounted 2014 Prom Dresses Provided By Innovative Company UWDress.com 2Health News:RBSEO Services Announces Affordable Website SEO Service at Only $175 2
... what do you get for the nut,that has everything, including ... Doctor Chuck talking therapy doll?, You can at once ... who needs it, their own personal and portable psychotherapist. The,Ask ... line, which could,earn you the undying gratitude of the rest ...
... Higher-risk Myelodysplastic Syndromes (MDS), Thalidomide in Multiple ... ... 6 Pharmion Corporation,(Nasdaq: PHRM ) reported today that data ... products will,be presented at the American Society of Hematology,s (ASH) 49th ...
... Arete Therapeutics Inc., a,privately-held biopharmaceutical company developing first-in-class ... and,metabolic diseases, today announced the appointment of Donald ... are very pleased to welcome Don to our ... will be of great benefit to the Company,as ...
... Company Projects Seven Products to Reach Sales of $1 Billion or More in ... 2008, - ... ... Gains plus Aggressive Deal-Making Result in Unprecedented ...
... StemCor Systems, Inc., a,medical device company ... that it has acquired U.S. Patent 6,849,051,"Devices ... and associated,know-how from USPure Sciences, LLC. The ... samples from bone cavities. The concept and,technologies ...
... 5 EpiCept Corporation,(Nasdaq and OMX Nordic Exchange: ... will present a company overview at the New ... & Specialty Pharma,Conference on December 12, 2007 at ... at the NYSSA,s headquarters at 1177 Avenue of ...
Cached Medicine News:Health News:The Cure for Holiday Stress 2Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 2Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 3Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 4Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 5Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 6Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 7Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 8Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 9Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 10Health News:Arete Therapeutics Appoints Donald Santel to Board of Directors 2Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 2Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 3Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 4Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 5Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 6Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 7Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 8Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 9Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 10Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 11Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 12Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 13Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 14Health News:StemCor Systems Announces Acquisition of Intellectual Property to Enhance Bone Marrow Aspiration Platform 2Health News:StemCor Systems Announces Acquisition of Intellectual Property to Enhance Bone Marrow Aspiration Platform 3Health News:EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference 2Health News:EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: